Replies to post #16618 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA submitted its 40mg Copaxone ANDA on the first day possible—i.e. immediately after TEVA's (now discredited) 40mg-Copaxone patents were entered into the FDA's Orange Book. So, at worst, MNTA filed on the same day as other 40mg-Copaxone ANDA filers.